Bellicum Pharmaceuticals Receives $20,000,000 Series B Round

  • Feed Type
  • Date
    3/12/2012
  • Company Name
    Bellicum Pharmaceuticals
  • Mailing Address
    6400 Fannin St. Houston, TX 77030
  • Company Description
    Bellicum Pharmaceuticals, Inc. is developing next generation therapeutic vaccines and other immunotherapeutic approaches for the treatment of cancer and chronic infectious diseases. Bellicum’s novel approach is to utilize precise knowledge of the signaling pathways that regulate the immune response to target specific factors that can influence the potency and duration of this response.
  • Website
    http://www.bellicum.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $20,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    The funding will be used to advance its lead CaspaCIDe and DeCIDe programs through Phase 2 clinical development.
  • M&A Terms
  • Venture Investor
    Remeditex Ventures
  • Venture Investor
    Undisclosed

Trending on Xconomy